Amylyx Pharmaceuticals, Inc. (AMLX) › Cost of RevenueAmylyx Pharmaceuticals, Inc. (AMLX) — Cost of RevenueAnnual figures by period end, from SEC filings.2022-12-31: $2.99M2023-12-31: $25.44M2024-12-31: $5.95M2025-12-31: $0$02022-12-31Cost of Revenue (USD)2025-12-31Period endedCost of RevenueChange YoYSource filing2025-12-31$0-100.0%2026-03-03From 2025-01-012024-12-31$5.95M-76.6%2026-03-03From 2024-01-012023-12-31$25.44M+750.0%2025-03-04From 2023-01-012022-12-31$2.99M—2024-02-22From 2022-01-01Other metrics: RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)